ArticleCardiovascular therapeutics2026
Predictive Value of Serum Pepsinogen and Gastrin-17 in Patients With Acute Coronary Syndrome for Post-Percutaneous Coronary Intervention Oral Dual Antiplatelet Therapy-Associated Upper Gastrointestinal Bleeding.
Article in Cardiovascular therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGastrin-17 (G-17) and serum pepsinogen (PG) are indicators that reflect the structure and function of the stomach mucosa. Although they have been linked to upper gastrointestinal bleeding (UGIB) in peptic ulcer disease, it is unknown how they relate to the risk of UGIB in patients with acute coronary syndrome (ACS) after dual antiplatelet treatment (DAPT) following percutaneous coronary intervention (PCI).
objectiveThis single-center, retrospective study aims to evaluate whether PG and G-17 as gastric mucosal assessment markers, are potentially associated with UGIB during DAPT following PCI in patients with ACS.
methodsThis study employed a retrospective analysis design and included 334 patients with ACS (2021-2023) from Xuzhou Medical University Affiliated Hospital, divided into UGIB group (69 patients) and non-UGIB group (265 patients). Clinical and laboratory data were collected. Multivariate logistic regression and ROC curve analysis were used to evaluate the associations of G-17, PRECISE-DAPT scores, ACS subtype, and P
resultsCompared with the non-UGIB group, G-17 levels and PRECISE-DAPT scores in the UGIB group were markedly higher, and ticagrelor was prescribed more commonly (p < 0.001). The area under the curve (AUC) of G-17, PRECISE-DAPT scores alone, and in combination were 0.734, 0.794, and 0.844, respectively; the AUC further increased to 0.878 after incorporating ticagrelor exposure, indicating that the combined assessment with ticagrelor exposure has superior exploratory value in identifying high-risk patients with UGIB (p < 0.05). Furthermore, the combined use of PPIs during DAPT reduced the incidence of UGIB (34.78% vs. 65.22%, p < 0.05), which serves as an important interfering factor for G-17 assessment.
conclusionHigher G-17 levels and PRECISE-DAPT scores were associated with UGIB during DAPT after PCI. Combined assessment with ticagrelor exposure showed exploratory value for identifying patients at higher bleeding risk, although PPIs use influenced model performance. Given the retrospective single-center design and limited sample size, these findings remain preliminary and require prospective multicenter validation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.